Kyowa Kirin PROSPER data show mogamulizumab eases CTCL symptoms

Kyowa Kirin has reported results from PROSPER, a real-world observational study of mogamulizumab (marketed as POTELIGEO) in adults with mycosis fungoides (MF) or Sézary syndrome (SS), showing patient-reported improvements in skin symptoms, sleep and health-related quality of life that persisted across the full 48-week study period. The data were presented at the 6th World Congress of Cutaneous Lymphomas in Montreal.

The study enrolled 73 patients with relapsed or refractory disease (41 with MF, 32 with SS) across 19 sites in six countries spanning North America, Europe and the Middle East. Symptom burden was tracked using a disease-specific diary and validated instruments including the MF/SS-CTCL-QoL questionnaire and the Brief Fatigue Inventory. Improvements in itch, flaking and redness all exceeded the minimum important difference threshold by week 4, with pain and quality-of-life scores reaching meaningful improvement by week 12.

By week 48, mean symptom scores had improved from baseline for skin itch (minus 2.5 points), flaking (minus 3.1), redness (minus 3.1) and pain (minus 1.7). Thirty percent of patients reported at least a two-point gain in sleep quality, and 37% reported improved body temperature regulation. Patients with SS also showed a significant improvement in total fatigue scores, reaching the minimum important difference by week 48, while fatigue among patients with MF changed little.

Clinical significance

Professor Julia Scarisbrick, honorary professor of dermatology at University Hospitals Birmingham NHS Foundation Trust and principal investigator, said the findings were encouraging because they captured impacts on everyday life beyond the skin alone. "Cutaneous T-cell lymphoma can affect far more than just the skin, impacting how patients feel and function every day," she said. "These findings from the PROSPER study are encouraging because they show that in patients with MF or SS, mogamulizumab can help ease symptoms that affect everyday life, and those improvements can be long-lasting."

The PROSPER design is notable for incorporating patient and caregiver input during the protocol stage, reflecting a broader industry shift toward patient-centric outcome selection in rare oncology trials. Angela Williams, global head of health economics and outcomes research at Kyowa Kirin, said real-world data of this kind capture dimensions of treatment experience that standard clinical-trial endpoints can miss, particularly for symptoms such as itch, sleep disruption and fatigue.

Market and competitive context

MF and SS together represent the most common subtypes of cutaneous T-cell lymphoma, itself a rare form of non-Hodgkin lymphoma. Treatment options in the relapsed or refractory setting remain limited. Mogamulizumab is a CCR4-targeting monoclonal antibody that received FDA approval for this indication in 2018, based on the MAVORIC Phase 3 trial. The PROSPER data extend the evidence base into routine clinical practice, where patient heterogeneity and treatment patterns differ from the controlled trial environment.

The broader CTCL treatment landscape includes brentuximab vedotin, histone deacetylase inhibitors such as romidepsin and vorinostat, and a small number of investigational agents in mid-stage development. For Kyowa Kirin, real-world quality-of-life evidence strengthens the commercial and payer argument for mogamulizumab at a point when health technology assessment bodies in Europe and elsewhere are placing increasing weight on patient-reported outcomes in rare-disease submissions. The company is a wholly owned subsidiary of Tokyo-listed Kyowa Kirin Co., which positions the drug as a core asset in its haematology and rare-disease franchise.